Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inogen IncINGN · Entity 2083 | EVP, Marketing | March 15, 2021 | March 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inogen Inc
Report date March 15, 2021 · Filed March 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,327 |
Ending reported balance
After 2021-03-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-03-15 · Exercise / conversion · Acquired 7,102 · Balance 44,429 Row 2 · 2021-03-15 · Sale · Disposed 4,050 · Balance 40,379 F1: Represents the weighted average share price of an aggregate total of 4,050 shares sold in the price range of $51.10 to $52.10 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2021-03-15 · Sale · Disposed 3,052 · Balance 37,327 F2: Represents the weighted average share price of an aggregate total of 3,052 shares sold in the price range of $52.11 to $52.42 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.62 · Expires 2021-03-31 | Direct | 0 |
Reported balance
After 2021-03-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-15 · Exercise / conversion · Disposed 7,102 · Balance 0 F3: Subject to the reporting person's continuing service, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month after March 1, 2014. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average share price of an aggregate total of 4,050 shares sold in the price range of $51.10 to $52.10 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2: Represents the weighted average share price of an aggregate total of 3,052 shares sold in the price range of $52.11 to $52.42 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Subject to the reporting person's continuing service, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month after March 1, 2014.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2018 Filed Aug 14, 2018 00:07 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 5,689 | $16.62 | $94,551.18 |
DisclosureSEC source: 0001209191-18-046520 · doc4.xml · nonDerivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2018 Filed Aug 14, 2018 00:07 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 5,054 | $8.37 | $42,301.98 |
DisclosureSEC source: 0001209191-18-046520 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 00:07 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 11,074 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-18-042253 · doc4.xml · derivative · entry 3 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,074 shares Expires 2020-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Subject to the reporting person's continued service, sixty percent (60%) of the shares subject to the option vested and became exercisable on the vesting commencement date, and thereafter, one thirtieth (1/30th) of the remaining shares subject to the option vested each month on the same day as the vesting commencement date, such that the shares subject to the option became fully vested and exercisable on the thirty (30) month anniversary of the vesting commencement date. The vesting commencement date for this option is February 24, 2010. This option is fully vested as of August 24, 2012. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 00:07 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 11,074 | $200.22 | $2,217,222.99 |
DisclosureSEC source: 0001209191-18-042253 · doc4.xml · nonDerivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,275 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F2 · price: Represents the weighted average share price of an aggregate total of 11,074 shares sold in the price range of $200.00 to $200.85 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 00:07 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 11,074 | $0.60 | $6,644.40 |
DisclosureSEC source: 0001209191-18-042253 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 21:22 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 8,056 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-18-038987 · doc4.xml · derivative · entry 4 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,074 Underlying: Common Stock · 8,056 shares Expires 2020-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the reporting person's continued service, sixty percent (60%) of the shares subject to the option vested and became exercisable on the vesting commencement date, and thereafter, one thirtieth (1/30th) of the remaining shares subject to the option vested each month on the same day as the vesting commencement date, such that the shares subject to the option became fully vested and exercisable on the thirty (30) month anniversary of the vesting commencement date. The vesting commencement date for this option is February 24, 2010. This option is fully vested as of August 24, 2012. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 21:22 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,300 | $191.58 | $249,056.99 |
DisclosureSEC source: 0001209191-18-038987 · doc4.xml · nonDerivative · entry 3 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,275 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F3 · price: Represents the weighted average share price of an aggregate total of 1,300 shares sold in the price range of $191.070 to $192.005 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 21:22 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 6,756 | $190.38 | $1,286,222.14 |
DisclosureSEC source: 0001209191-18-038987 · doc4.xml · nonDerivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,575 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F2 · price: Represents the weighted average share price of an aggregate total of 6,756 shares sold in the price range of $190.00 to $190.70 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 21:22 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 8,056 | $0.60 | $4,833.60 |
DisclosureSEC source: 0001209191-18-038987 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 23:19 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 1,846 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-18-038685 · doc4.xml · derivative · entry 3 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,130 Underlying: Common Stock · 1,846 shares Expires 2020-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Subject to the reporting person's continued service, sixty percent (60%) of the shares subject to the option vested and became exercisable on the vesting commencement date, and thereafter, one thirtieth (1/30th) of the remaining shares subject to the option vested each month on the same day as the vesting commencement date, such that the shares subject to the option became fully vested and exercisable on the thirty (30) month anniversary of the vesting commencement date. The vesting commencement date for this option is February 24, 2010. This option is fully vested as of August 24, 2012. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 23:19 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,846 | $190.04 | $350,820.49 |
DisclosureSEC source: 0001209191-18-038685 · doc4.xml · nonDerivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,275 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F2 · price: Represents the weighted average share price of an aggregate total of 1,846 shares sold in the price range of $190.00 to $190.16 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 23:19 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 1,846 | $0.60 | $1,107.60 |
DisclosureSEC source: 0001209191-18-038685 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:36 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 1,171 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-18-037041 · doc4.xml · derivative · entry 10 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,976 Underlying: Common Stock · 1,171 shares Expires 2020-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Subject to the reporting person's continued service, sixty percent (60%) of the shares subject to the option vested and became exercisable on the vesting commencement date, and thereafter, one thirtieth (1/30th) of the remaining shares subject to the option vested each month on the same day as the vesting commencement date, such that the shares subject to the option became fully vested and exercisable on the thirty (30) month anniversary of the vesting commencement date. The vesting commencement date for this option is February 24, 2010. This option is fully vested as of August 24, 2012. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:36 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,200 | $190.43 | $228,519.00 |
DisclosureSEC source: 0001209191-18-037041 · doc4.xml · nonDerivative · entry 9 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,275 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F8 · price: Represents the weighted average share price of an aggregate total of 1,200 shares sold in the price range of $190.11 to $190.82 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:36 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,000 | $189.07 | $378,133.00 |
DisclosureSEC source: 0001209191-18-037041 · doc4.xml · nonDerivative · entry 8 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,475 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F7 · price: Represents the weighted average share price of an aggregate total of 2,000 shares sold in the price range of $188.54 to $189.50 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:36 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,250 | $187.81 | $234,764.63 |
DisclosureSEC source: 0001209191-18-037041 · doc4.xml · nonDerivative · entry 7 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,475 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F6 · price: Represents the weighted average share price of an aggregate total of 1,250 shares sold in the price range of $187.50 to $188.05 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:36 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,141 | $186.28 | $398,834.69 |
DisclosureSEC source: 0001209191-18-037041 · doc4.xml · nonDerivative · entry 6 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,725 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F5 · price: Represents the weighted average share price of an aggregate total of 2,141 shares sold in the price range of $186.00 to $186.84 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:36 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 100 | $184.49 | $18,449.25 |
DisclosureSEC source: 0001209191-18-037041 · doc4.xml · nonDerivative · entry 5 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,866 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:36 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,492 | $183.99 | $458,500.59 |
DisclosureSEC source: 0001209191-18-037041 · doc4.xml · nonDerivative · entry 4 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,966 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F4 · price: Represents the weighted average share price of an aggregate total of 2,492 shares sold in the price range of $183.46 to $184.44 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:36 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 816 | $182.49 | $148,910.29 |
DisclosureSEC source: 0001209191-18-037041 · doc4.xml · nonDerivative · entry 3 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,458 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F3 · price: Represents the weighted average share price of an aggregate total of 816 shares sold in the price range of $182.27 to $183.16 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:36 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,171 | $190.42 | $222,981.82 |
DisclosureSEC source: 0001209191-18-037041 · doc4.xml · nonDerivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,274 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2018. F2 · price: Represents the weighted average share price of an aggregate total of 1,171 shares sold in the price range of $190.05 to $190.82 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:36 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 1,171 | $0.60 | $702.60 |
DisclosureSEC source: 0001209191-18-037041 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 01:11 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 5,798 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001209191-18-017873 · doc4.xml · derivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,798 shares Expires 2018-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Subject to the reporting person's continuing service, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is January 1, 2008. This option is fully vested as of January 1, 2012. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 01:11 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 5,798 | $2.40 | $13,915.20 |
DisclosureSEC source: 0001209191-18-017873 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 22:44 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 2,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017401 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,476 F1 · shares: The reported securities represent shares of restricted stock, 25% of which shall vest on March 1, 2019, and 1/16th of which shall vest every three months thereafter on the 1st day of the month, subject in each case to the reporting person remaining a service provider through each such applicable vesting date. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:52 UTC | Inogen Inc INGN · Entity 2083 | Tax withholdingCommon Stock | 393 | $118.33 | $46,503.69 |
DisclosureSEC source: 0001209191-18-015937 · doc4.xml · nonDerivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,345 F2 · shares: The reported shares were withheld in a net issuance to cover the Reporting Person's tax withholding liability in connection with the portion of the 2017 performance-based restricted stock award that was earned and vested on March 1, 2018. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:52 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 1,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-015937 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,738 F1 · shares: The reported securities represent shares earned and vested on March 1, 2018 based on achievement of the financial performance conditions for the 2017 fiscal year that were approved as part of the 2017 performance-based restricted stock award granted on August 8, 2017. Read SEC document |
| December 11, 2017 Filed Dec 12, 2017 23:43 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001209191-17-065267 · doc4.xml · derivative · entry 5 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,480 Underlying: Common Stock · 10,000 shares Expires 2022-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the reporting person's continuing service, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is April 1, 2012. F6 · derivative.expiration_date: Form 3 reported an incorrect expiration date of 03/28/2022. Read SEC document |
| December 11, 2017 Filed Dec 12, 2017 23:43 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 800 | $117.95 | $94,356.00 |
DisclosureSEC source: 0001209191-17-065267 · doc4.xml · nonDerivative · entry 4 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2017. F4 · price: Represents the weighted average share price of an aggregate total of 800 shares sold in the price range of $117.72 to $118.54 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 12, 2017 23:43 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 5,400 | $117.07 | $632,153.16 |
DisclosureSEC source: 0001209191-17-065267 · doc4.xml · nonDerivative · entry 3 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2017. F3 · price: Represents the weighted average share price of an aggregate total of 5,400 shares sold in the price range of $116.67 to $117.42 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 12, 2017 23:43 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 3,800 | $116.22 | $441,632.96 |
DisclosureSEC source: 0001209191-17-065267 · doc4.xml · nonDerivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 3,800 shares sold in the price range of $115.6350 to $116.6300 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 12, 2017 23:43 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 10,000 | $0.81 | $8,100.00 |
DisclosureSEC source: 0001209191-17-065267 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · derivative · entry 11 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 5,000 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is May 1, 2016. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $38.54 | $0.00 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · derivative · entry 10 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 10,000 shares Expires 2022-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month on the same day as the vesting commencement date. The vesting commencement date for this option is May 1, 2015. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.62 | $0.00 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · derivative · entry 9 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,791 Underlying: Common Stock · 10,000 shares Expires 2021-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Subject to the reporting person's continuing service, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month after March 1, 2014. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · derivative · entry 8 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,054 Underlying: Common Stock · 10,000 shares Expires 2023-10-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the reporting person's continuing service, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is October 1, 2013 F6 · derivative.expiration_date: Previous Form 4 filed on June 5, 2017 reported an incorrect expiration date of 10/10/2023. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,850 | $118.54 | $219,299.93 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · nonDerivative · entry 7 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2017. F4 · price: Represents the weighted average share price of an aggregate total of 1,850 shares sold in the price range of $118.255 to $119.41 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 4,330 | $117.86 | $510,313.88 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · nonDerivative · entry 6 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,450 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2017. F3 · price: Represents the weighted average share price of an aggregate total of 4,330 shares sold in the price range of $117.16 to $118.14 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 28,820 | $116.49 | $3,357,299.44 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · nonDerivative · entry 5 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,780 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 28,820 shares sold in the price range of $116.03 to $117.02 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 5,000 | $44.19 | $220,950.00 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · nonDerivative · entry 4 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 10,000 | $38.54 | $385,400.00 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · nonDerivative · entry 3 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 10,000 | $16.62 | $166,200.00 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · nonDerivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:05 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 10,000 | $8.37 | $83,700.00 |
DisclosureSEC source: 0001209191-17-062013 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 20:57 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 3,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049007 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,600 F1 · shares: The reported securities represent shares of restricted stock, 25% of which shall vest on September 1, 2018, and 1/16th of which shall vest every three months thereafter on the 1st of the month. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 19:20 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0001209191-17-037633 · doc4.xml · derivative · entry 3 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 10,000 shares Expires 2023-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to the reporting person's continuing service, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is October 1, 2013 Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 19:20 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 10,000 | $90.00 | $900,000.00 |
DisclosureSEC source: 0001209191-17-037633 · doc4.xml · nonDerivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,185 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2016. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 19:20 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 10,000 | $8.37 | $83,700.00 |
DisclosureSEC source: 0001209191-17-037633 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:27 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.62 | $0.00 |
DisclosureSEC source: 0001209191-17-028183 · doc4.xml · derivative · entry 3 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,791 Underlying: Common Stock · 10,000 shares Expires 2021-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to the reporting person's continuing service, 1/48th of the total shares subject to the option shall vest every month after March 1, 2014. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:27 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 10,000 | $80.00 | $800,000.00 |
DisclosureSEC source: 0001209191-17-028183 · doc4.xml · nonDerivative · entry 2 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,185 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2016. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:27 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 10,000 | $16.62 | $166,200.00 |
DisclosureSEC source: 0001209191-17-028183 · doc4.xml · nonDerivative · entry 1 Myers Byron · CIK 0001596086 · EVP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.